Stage-dependent expression of PI3K/Akt-pathway genes in neuroblastoma

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 609-616

  Fransson, Susanne ^a   Abel, Frida ^a   Kogner, Per ^b   Martinsson, Tommy ^a   Ejeskär, Katarina ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

Expression; Neuroblastoma; Phosphoinositide 3 kinase; Signaling

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110; PROTEIN P85;

ARTICLE; CANCER STAGING; CLUSTER ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; NEUROBLASTOMA; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84873694384     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1732     Document Type: Article

References (46)

1. Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619, 2006.
2. Saal LH, Johansson P, Holm K, et al: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 104: 7564-7569, 2007.
3. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
4. Aleskandarany MA, Rakha EA, Ahmed MA, et al: PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat 122: 45-53, 2010.
5. Kato S, Iida S, Higuchi T, et al: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778, 2007.
6. Chapuis N, Tamburini J, Cornillet-Lefebvre P, et al: Autocrine IGF 1/IGF 1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti IGF 1R antibody. Haematologica 95: 415-423, 2010.
7. Muders MH, Zhang H, Wang E, Tindall DJ and Datta K: Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Res 69: 6042-6048, 2009.
8. Puri N and Salgia R: Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 7: 9, 2008.
9. De Preter K, Vandesompele J, Heimann P, et al: Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol 7: R84, 2006.
10. Dam V, Morgan BT, Mazanek P and Hogarty MD: Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer 6: 177, 2006.
11. Moritake H, Horii Y, Kuroda H and Sugimoto T: Analysis of PTEN/MMAC1 alteration in neuroblastoma. Cancer Genet Cytogenet 125: 151-155, 2001.
12. Caren H, Fransson S, Ejeskar K, Kogner P and Martinsson T: Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer 97: 1416-1424, 2007.
13. Boller D, Schramm A, Doepfner KT, et al: Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clin Cancer Res 14: 1172-1181, 2008.
14. Fransson S, Martinsson T and Ejeskar K: Neuroblastoma tumors with favorable and unfavorable outcomes: significant differences in mRNA expression of genes mapped at 1p36.2. Genes Chromosomes Cancer 46: 45-52, 2007.
15. Johnsen JI, Segerstrom L, Orrego A, et al: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27: 2910-2922, 2008.
16. Opel D, Poremba C, Simon T, Debatin KM and Fulda S: Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745, 2007.
17. Brodeur GM, Minturn JE, Ho R, et al: Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 15: 3244-3250, 2009.
18. Fredlund E, Ringner M, Maris JM and Pahlman S: High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 105: 14094-14099, 2008.
19. Hedborg F, Bjelfman C, Sparen P, Sandstedt B and Pahlman S: Biochemical evidence for a mature phenotype in morphologically poorly differentiated neuroblastomas with a favourable outcome. Eur J Cancer 31A: 435-443, 1995.
20. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
21. Chesler L, Schlieve C, Goldenberg DD, et al: Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res 66: 8139 8146, 2006.
22. Yamamoto M, Acevedo-Duncan M, Chalfant CE, Patel NA, Watson JE and Cooper DR: The roles of protein kinase C beta I and beta II in vascular smooth muscle cell proliferation. Exp Cell Res 240: 349-358, 1998.
23. Borner C, Ueffing M, Jaken S, Parker PJ and Weinstein IB: Two closely related isoforms of protein kinase C produce reciprocal effects on the growth of rat fibroblasts. Possible molecular mechanisms. J Biol Chem 270: 78-86, 1995.
24. Zeidman R, Pettersson L, Sailaja PR, et al: Novel and classical protein kinase C isoforms have different functions in proliferation, survival and differentiation of neuroblastoma cells. Int J Cancer 81: 494-501, 1999.
25. Svensson K, Zeidman R, Troller U, Schultz A and Larsson C: Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation. Cell Growth Differ 11: 641-648, 2000.
26. Mak NK, Lung HL, Wong RN, Leung HW, Tsang HY and Leung KN: Expression of protein kinase C isoforms in euxanthone-induced differentiation of neuroblastoma cells. Planta Med 67: 400-405, 2001.
27. Macfarlane DE and Manzel L: Activation of beta-isozyme of protein kinase C (PKC beta) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. Studies with PKC beta-defective PET mutant. J Biol Chem 269: 4327-4331, 1994.
28. Liu YF, Paz K, Herschkovitz A, et al: Insulin stimulates PKCzeta mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. J Biol Chem 276: 14459 14465, 2001.
29. Nazarenko I, Jenny M, Keil J, et al: Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer. Mol Cancer Res 8: 919-934, 2010.
30. Guo H, Gu F, Li W, et al: Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem 109: 203-213, 2009.
31. Mei Y, Wang Z, Zhang L, et al: Regulation of neuroblastoma differentiation by forkhead transcription factors FOXO1/3/4 through the receptor tyrosine kinase PDGFRA. Proc Natl Acad Sci USA 109: 4898-4903, 2012.
32. Pahlman S, Johansson I, Westermark B and Nister M: Platelet derived growth factor potentiates phorbol ester-induced neuronal differentiation of human neuroblastoma cells. Cell Growth Differ 3: 783-790, 1992.
33. Yu J, Ustach C and Kim HR: Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36: 49-59, 2003.
34. Barber DF, Alvarado-Kristensson M, Gonzalez-GarciaA, Pulido R and Carrera AC: PTEN regulation, a novel function for the p85 subunit of phosphoinositide 3-kinase. Sci STKE 2006: pe49, 2006.
35. Rabinovsky R, Pochanard P, McNear C, et al: p85 associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol 29: 5377-5388, 2009.
36. Chagpar RB, Links PH, Pastor MC, et al: Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 107: 5471-5476, 2010.
37. Taniguchi CM, Winnay J, Kondo T, et al: The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res 70: 5305-5315, 2010.
38. Luo J and Cantley LC: The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 4: 1309-1312, 2005.
39. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA and Backer JM: Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18: 1379-1387, 1998.
40. Shekar SC, Wu H, Fu Z, et al: Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit. J Biol Chem 280: 27850-27855, 2005.
41. Jimenez C, Jones DR, Rodriguez-Viciana P, et al: Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17: 743-753, 1998.
42. Philp AJ, Campbell IG, Leet C, et al: The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426-7429, 2001.
43. Lopez-Carballo G, Moreno L, Masia S, Perez P and Barettino D: Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem 277: 25297-25304, 2002.
44. Evangelopoulos ME, Weis J and Kruttgen A: Signalling pathways leading to neuroblastoma differentiation after serum withdrawal: HDL blocks neuroblastoma differentiation by inhibition of EGFR. Oncogene 24: 3309-3318, 2005.
45. Evangelopoulos ME, Weis J and Kruttgen A: Mevastatin-induced neurite outgrowth of neuroblastoma cells via activation of EGFR. J Neurosci Res 87: 2138-2144, 2009.
46. Wilzen A, Nilsson S, Sjoberg RM, Kogner P, Martinsson T and Abel F: The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol 34: 697-705, 2009.